Eliquis (Apixaban) Received New Indications for DVT Prophylaxis After Hip/Knee Replacement Surgery and Risk Reduction for Recurrent DVT and PELisa A. RaedlerRph
In the European Union (EU) and by the FDA, apixaban currently holds approval as a prophylactic agent following hip and knee replacement surgeries. The recommended dosage for DVT prophylaxis post-hip or knee replacement surgery is 2.5 mg orally twice daily. It is advised to initiate the dosage ...
Prophylaxis Of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. Treatment Of Deep Vein Thrombosis ELIQUIS ...
Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery, and Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION...
Postoperative Prophylaxis of DVT/PE Indicated following hip or knee replacement surgery Initial: Give 2.5 mg PO 12-24 hr after surgery Duration of therapy (hip replacement): 2.5 mg PO BID for 35 days Duration of therapy (knee replacement): 2.5 mg PO BID for 12 days Renal impairment, includi...
产地国家:美国 处方药:是 所属类别:5毫克/片 60片/瓶 包装规格:5毫克/片 60片/瓶 计价单位:瓶 生产厂家中文参考译名:BRISTOL
ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following...
Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery, and Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION...
Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery, and Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE No dose adjustment is recommended for patients with renal impairment, including those with ESRD on dialysis [seeDOSAGE AND ADMINISTRATION...
Currently, apixaban is US FDA-approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery, for the treatment of DVT and PE, and...